TheraRadar
Data updated: May 26, 2026

Spikevax (covid-19 vaccine, mrna)

Approved 2022-01-30
1
Indication
--
Phase 3 Trials
4
Years on Market

Details

Status
Disc
First Approved
2022-01-30
Routes
Intramuscular
Dosage Forms
Injection

Spikevax Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2022 to 2022
Jan 2022 ORIGINAL
Update · CBER biologic (Purple Book)

What Spikevax Treats

1 FDA approvals

Originally approved for its first indication in 2022 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT05075538 I-SPARC IJB-COVID-001 2021-003710-39 Ph 4 terminated COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Spikevax FDA Label Details

Track Spikevax with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.